Evidence map›Paper›PMID 35239124›Full record

ArticleEndocrine2022

The potential impact of COVID-19 on thyroid gland volumes among COVID-19 survivors.

Emre Urhan, Zuleyha Karaca, Canan Sehit Kara, Zeynep Ture Yuce, Kursad Unluhizarci

Open access · bronzeAbstract read
In one paragraph

Article in Endocrine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Thyroid dysfunction in COVID-19.Nature reviews. Endocrinology · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Emre UrhanDepartment of Endocrinology, Erciyes University Medical School, Kayseri, Turkey.
Zuleyha KaracaDepartment of Endocrinology, Erciyes University Medical School, Kayseri, Turkey.
Canan Sehit KaraDepartment of Endocrinology, Erciyes University Medical School, Kayseri, Turkey.
Zeynep Ture YuceDepartment of Infectious Diseases and Clinical Microbiology, Erciyes University Medical School, Kayseri, Turkey.
Kursad UnluhizarciDepartment of Endocrinology, Erciyes University Medical School, Kayseri, Turkey. kursad@erciyes.edu.tr.ORCID 0000-0003-2024-7433
Erciyes University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeData about the effects of COVID-19 on the endocrine system are increasing over time. In the present study, we investigated the effects of COVID-19 on the thyroid gland among COVID-19 survivors by comparing them with healthy subjects.

methodsAdult COVID-19 survivors who were managed and followed up in the Infectious Disease clinic were asked to participate in this study. COVID-19 survivors were recruited via a convenience sampling and those who agreed to participate in this study were seen by endocrinologists for assessments. The blood tests were obtained for thyroid antibodies and thyroid function tests. Thyroid ultrasonography (USG) was done by the same physician. The ellipsoid formula was used for the calculation of thyroid gland volume.

results64 adult COVID-19 survivors and 70 control subjects were enrolled in the study. The COVID-19 survivors were evaluated at median 5.7 months (IQR: 4-6.5) (range: 2-7 months) after acute infection. The mean thyroid gland volume was significantly lower in COVID-19 survivors (10.3 ± 3.4 mL) than in the controls (14 ± 5.3 mL) (p = 0.001). There was no significant difference in free triiodothyronine (fT3), free thyroxine (fT4) and thyroid-stimulating hormone (TSH) levels between the groups. Among the twelve patients who had thyroid function evaluated in acute COVID-19, fT3 values were lower in acute COVID-19 than at the time of USG evaluation (3.04 ± 0.41 vs 3.47 ± 0.31 pg/mL), (p = 0.02). Among COVID-19 survivors, mild TSH elevation was detected in 4 (6.2%) patients and all of the other COVID-19 survivors (93.7%) were euthyroid.

conclusionsAt 6 months after acute COVID, COVID-19 survivors had smaller thyroid gland volume than healthy controls, and only a few of the COVID-19 survivors had abnormal thyroid function.

Indexed as

COVID-19AdultHumansSARS-CoV-2SurvivorsThyroid Function TestsThyroid GlandThyrotropinThyroxineTriiodothyronineThyrotropinThyroxineTriiodothyronineCOVID-19SARS-CoV-2Thyroid function testsThyroid gland volume

Identifiers

PMID35239124
PMCPMC8892112
OpenAlexW4214841980

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.